Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

This study has been completed.
National Institute on Drug Abuse (NIDA)
Reckitt and Colman
Information provided by:
VA Office of Research and Development Identifier:
First received: December 29, 2000
Last updated: January 20, 2009
Last verified: February 2003
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: January 2002
  Estimated Primary Completion Date: No date given